Amphista Therapeutics, a company focused on next generation targeted protein degradation (TPD) approaches, has appointed Antony Mattessich as CEO and board member. The appointment will steer Amphista through its next…
Amphista Therapeutics, a company focused on next generation targeted protein degradation (TPD) approaches, has appointed Antony Mattessich as CEO and board member. The appointment will steer Amphista through its next…
…
…